Gene expression has been analyzed by throughput DMA microarrays which simultaneously monitor the expression of thousands of genes. However, mRNA expression of a gene may not correlate with protein expression because of the differences in rates of mRNA translation/degradation and post-translational modification. Mass spectrometry with/without prior separation of proteins has been developed but the burden of the experiment is on the user. During Phase I, we successfully developed and commercialized rat drug-metabolizing enzyme antibody microarrays containing 76 antibodies for cytochromes P450 and co-enzymes, phase II drug-metabolizing enzymes, apoptosis-related proteins, house-keeping proteins and Flag internal control protein. During Phase II, we will (1) further improve rat polyacrylamide-based hydrogel arrays, (2) improve and develop additional arrays with chips coated with various surface materials, (3) develop and explore signal enhancing methods, (4) develop mouse drug-metabolizing enzyme antibody microarrays, (5) develop human drug-metabolizing enzyme antibody microarrays and (6) explore utility of antibody arrays and discover markers for 5 classes of toxicants. The targeted arrays produced with form-specific antibodies of closely related proteins involved with drug and environmental toxicant metabolism will be an invaluable tool for toxicoproteomics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44ES013805-03
Application #
7120162
Study Section
Special Emphasis Panel (ZRG1-ISD (01))
Program Officer
Heindel, Jerrold
Project Start
2005-03-01
Project End
2008-08-31
Budget Start
2006-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$275,268
Indirect Cost
Name
Detroit R & D, Inc.
Department
Type
DUNS #
030673508
City
Detroit
State
MI
Country
United States
Zip Code
48201